These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 2946507)

  • 1. Antihypertensive activity of isradipine in humans: a new dihydropyridine calcium channel antagonist.
    Nelson EB; Pool JL; Taylor AA
    Clin Pharmacol Ther; 1986 Dec; 40(6):694-7. PubMed ID: 2946507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of isradipine (PN 200-110) in mild to moderate hypertension.
    Winer N; Thys-Jacobs S; Kumar R; Davidson WD; Grayson M; Harris C; Walker D; Itskovitz H; Gonasun L
    Clin Pharmacol Ther; 1987 Oct; 42(4):442-8. PubMed ID: 2959426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the new calcium entry blocker isradipine (PN 200-110) in essential hypertension.
    Staessen J; Lijnen P; Fagard R; Hespel P; Tan WP; Devos P; Amery A
    J Cardiovasc Pharmacol; 1989 Feb; 13(2):271-6. PubMed ID: 2468957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The calcium antagonist isradipine in the therapy of hypertension. A double-blind crossover comparison with nifedipine.
    Welzel D; Burger KJ
    Drugs; 1990; 40 Suppl 2():60-4. PubMed ID: 2150644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of the new calcium antagonist isradipine in essential hypertension.
    Kirch W; Burger KJ; Weidinger G; Welzel D
    J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S55-9. PubMed ID: 1695304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term renal effects of isradipine, a calcium entry blocker, in essential hypertension.
    Persson B; Wysocki M; Andersson OK
    J Cardiovasc Pharmacol; 1989 Jul; 14(1):22-4. PubMed ID: 2475710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive effect of isradipine in combination with captopril in hypertensive patients.
    Eggertsen R; Svensson A; Dahlöf B; Hansson L
    Am J Med; 1989 Apr; 86(4A):124-6. PubMed ID: 2523647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of essential hypertension with PN 200-110 (isradipine).
    Hamilton BP
    Am J Cardiol; 1987 Jan; 59(3):141B-145B. PubMed ID: 2949585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive effect of a new dihydropyridine calcium antagonist, PN 200-110 (isradipine), combined with pindolol.
    Hansson L; Dahlof B
    Am J Cardiol; 1987 Jan; 59(3):137B-140B. PubMed ID: 2949584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium antagonists as first-line antihypertensive agents: a placebo-controlled, comparative trial of isradipine and nifedipine.
    Welzel D; Burger KJ; Weidinger G
    J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S70-4. PubMed ID: 1695308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood pressure control and haemodynamic adaptation with the dihydropyridine calcium antagonist isradipine: a controlled study in middle-aged hypertensive men.
    Andersson OK; Persson B; Hedner T; Aurell M; Wysocki M
    J Hypertens; 1989 Jun; 7(6):465-9. PubMed ID: 2528578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of isradipine in hypertension.
    Shepherd AM; Carr AA; Davidov M; Hamilton J; Schnaper H; Velasquez M; Brockway B; Prisant LM; Hamilton B; Gonasun L
    J Cardiovasc Pharmacol; 1989 Apr; 13(4):580-5. PubMed ID: 2470995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the safety and efficacy of isradipine in elderly patients with essential hypertension. The British Isradipine Hypertension Group.
    Am J Med; 1989 Apr; 86(4A):110-4. PubMed ID: 2523644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An acute dose-response pharmacodynamic evaluation of orally administered isradipine (PN-200-110) in hypertensive patients.
    McMahon FG; Vargas R; Ryan JR; Miller H; Faraday S
    J Clin Pharmacol; 1988 Jul; 28(7):664-6. PubMed ID: 2975291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placebo-controlled trial of once-a-day isradipine monotherapy in mild to moderately severe hypertension.
    Winer N; Kirkendall WM; Canosa FL; Lewin AJ; McMahon FG; Carr AA; Cohen M
    J Clin Pharmacol; 1990 Nov; 30(11):1006-11. PubMed ID: 2147029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central hemodynamics and brachial artery compliance during therapy with isradipine, a new calcium antagonist.
    Andersson OK; Persson B; Widgren BR; Wysocki M
    J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S87-9. PubMed ID: 1695312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved blood pressure control with isradipine in hypertensive patients treated with pindolol.
    Frithz G; Aström B; Dahlöf B; Hansson L; Tollin C; Himanen P; Sundstedt CD
    Am J Med; 1989 Apr; 86(4A):115-8. PubMed ID: 2523645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isradipine: overall clinical experience in hypertension in the United States.
    Miller H
    J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S60-4. PubMed ID: 1695305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter evaluation of the safety and efficacy of isradipine and atenolol in the treatment of hypertension. Isradipine in Hypertension Study Group.
    Am J Med; 1989 Apr; 86(4A):119-23. PubMed ID: 2523646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isradipine: overall clinical experience in hypertension in the United States.
    Miller H
    Am J Hypertens; 1991 Feb; 4(2 Pt 2):135S-139S. PubMed ID: 1827004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.